Trading Report: The Atyr Pharma Inc. (LIFE) Lowered to “Hold” at Zacks Investment Research

The Atyr Pharma Inc. (LIFE) Lowered to “Hold” at Zacks Investment Research

Zacks Investment Research cut shares of Atyr Pharma Inc. (NASDAQ:LIFE) from a buy rating to a hold rating in a research note issued to investors on Wednesday.

According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “

A number of other brokerages have also recently commented on LIFE. JPMorgan Chase & Co. decreased their price target on Atyr Pharma from $15.00 to $10.00 and set an overweight rating on the stock in a research note on Thursday, August 11th. Citigroup Inc. boosted their target price on Atyr Pharma from $3.00 to $4.00 and gave the company a neutral rating in a research note on Tuesday, August 16th. Finally, BMO Capital Markets set a $8.00 target price on Atyr Pharma and gave the company a hold rating in a research note on Thursday, October 6th. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Atyr Pharma has an average rating of Hold and an average target price of $6.50.

Shares of Atyr Pharma (NASDAQ:LIFE) opened at 2.86 on Wednesday. The stock has a 50 day moving average of $3.11 and a 200-day moving average of $3.24. The company’s market cap is $67.83 million. Atyr Pharma has a 12 month low of $2.48 and a 12 month high of $13.26.

Atyr Pharma (NASDAQ:LIFE) last released its earnings results on Wednesday, August 10th. The company reported ($0.65) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.71) by $0.06. Equities analysts forecast that Atyr Pharma will post ($2.56) earnings per share for the current year.

Large investors have recently modified their holdings of the company. A.R.T. Advisors LLC boosted its stake in shares of Atyr Pharma by 88.8% in the second quarter. A.R.T. Advisors LLC now owns 39,143 shares of the company’s stock valued at $108,000 after buying an additional 18,410 shares during the last quarter. State Street Corp boosted its stake in shares of Atyr Pharma by 51.8% in the first quarter. State Street Corp now owns 68,285 shares of the company’s stock valued at $270,000 after buying an additional 23,290 shares during the last quarter. GSA Capital Partners LLP purchased a new stake in shares of Atyr Pharma during the second quarter valued at $101,000. Bridgeway Capital Management Inc. purchased a new stake in shares of Atyr Pharma during the second quarter valued at $133,000. Finally, Jackson Park Capital LLC purchased a new stake in shares of Atyr Pharma during the second quarter valued at $183,000. 44.75% of the stock is currently owned by institutional investors.

Atyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Related posts

Leave a Comment